SCHEMBL10144059

SCHEMBL10144059

CC(CC(=O)Nc1ccccc1Cl)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.61
▸ ALDH1A1 P00352 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ KCNQ2 O43526 1/20 0.57
▸ P2RX7 Q99572 1/20 0.56
▸ HTT P42858 3/20 0.55
▸ CYP1A2 P05177 2/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ CYP2D6 P10635 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ CASR P41180 1/20 0.52
▸ SCN3A Q9NY46 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4268472 0.86 KMT2A (0.60) MEN1KMT2ANPSR1ALDH1A1HPGD
SCHEMBL27735382 0.84 MEN1 (0.58) MEN1KMT2ANPSR1ALDH1A1HPGD
SCHEMBL6009094 0.81 KDM4E (0.55) MEN1KMT2ANPSR1ALDH1A1HPGD
SCHEMBL6009091 0.81 KDM4E (0.55) MEN1KMT2ANPSR1ALDH1A1HPGD
SCHEMBL9311985 0.76 KMT2A (0.75) MEN1KMT2AALDH1A1HPGDP2RX7
SCHEMBL13901352 0.76 KMT2A (0.55) MEN1KMT2ANPSR1ALDH1A1HPGD
SCHEMBL2049574 0.75 HPGD (0.59) ALDH1A1HPGDHTTCYP3A4CYP2C19
SCHEMBL29389982 0.75 KMT2A (0.68) MEN1KMT2AALDH1A1HPGDHTT
SCHEMBL17434797 0.75 KMT2A (0.68) MEN1KMT2AALDH1A1HPGDHTT
SCHEMBL5186995 0.75 MEN1 (0.68) MEN1KMT2AHPGDKCNQ2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS BIOMARIN PHARMACEUTICAL INC. 2012-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS ENGASE, GALNT1, GALNT13 MEN1 3791/4885KMT2A 1652/4885NPSR1 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback